New HF drug

Discussion in 'Novartis' started by Anonymous, Nov 27, 2014 at 9:18 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Keep drinking that Novartis Kool Aid until you wise up after getting your pink slip.
     

  2. Anonymous

    Anonymous Guest

    Mixed reports on the study design. Once again the data will be debated.
    Will manage care cover the cost of the new drug ? My prediction is that the FDA will ask for more information. It just does not seem to be a clear cut study design and thus the data could be misleading.
     
  3. Anonymous

    Anonymous Guest

    Confusion and re-direction is the Novartis way! It's interesting that these poor or questionable trial designs began with Ilaris in gout through LCZ. Seems to be a common pattern or person of miss-direction.
     
  4. Anonymous

    Anonymous Guest

    Sacubitril is a novel agent, do you honestly think the researchers, scientists etc..don't know what this med can & can't do? If it had any efficacy by itself they would have designed a trial to show it. Get it approved them move on to combo's years down the road. What this appears to demonstrate is that sacubitril is a POS, possibly toxic or at the very least leads to an acceleration of alzheimers.
    The study basically said if you pay some hack/money grubbing whore a few hundred K or a million+, they can find the oldest most ancient ACEI dose it modestly & compare it to the highest dose of an ARB showing about an actual 4% difference which can possibly be attributed to the additional lowering of BP effect vs the sacubitril component or any phantom synergy.
    That's just for starters there were so many design flaws & dubious undisclosed paid NVS participants it's surprising they didn't just pull another "Japanese style" trial out of their ass.
    I'd venture to say if they dosed a higher dose of ramapril with HCTZ or even the highest dose irbesaratn HCT it would have smoked this lame combo without possible increase in Alzheimer's.
    They should have code named it ALZ696
    What's sad is all the soulless desperate lemmings lining up to fleece patients & the healthcare system to keep the paychecks rolling.
    Estimated at $7 a day so appx $220 a month Vs. a plethora of equally effective generic options for $10-30 a month.
    Remember that when someone's grandmother or grandfather gets fleeced out of an extra 2K a year because some newly minted speaker "expert" RX's this piece of garbage while you sleep soundly
     
  5. Anonymous

    Anonymous Guest

    Sounds like you are pretty biased anyways. Nobody is going to listen to someone that uses the word "fleeced" or puts "expert" in quotes when talking about medical professionals that have been practicing for decades.
    Nobody cares what you would venture to say about a different study design and what might have happened. Nice try at being a fear monger by throwing out the Alzheimer's bs that you have absolutely zero evidence to support.
     
  6. Anonymous

    Anonymous Guest

    Novartis may never get out of paying fines on Diovan mispromotion and buying the business with every class of customer! Marketing the drug for kidney protection when the studies being done in Houston showed no renal protection and heart failure was a joke! Valturna certainly solidified our CV franchise! Keep them in the dark is our mantra!
     
  7. Anonymous

    Anonymous Guest

    Biased or not, dont be so blinded that this study design is fixed to make this drug even look half decent as the so called medical professionals that have been studying for years are getting paid big $ to make it look so. The only people that will use it are the "kols" and we know why. Just like Tekturna.
     
  8. Anonymous

    Anonymous Guest

    Professionals? LMAO !!!! They paid PA's & NP's barely out of school along with 1000's of other so called 'x-spurts'. Clowns